News – Page 3 – Alligator Bioscience

2020-08-27

Regulatory

Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study

Lund, Sweden, August 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical ...

2020-08-25

Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) invites to a virtual R&D Day on August 27 at 2:00 p.m. – ...

2020-08-25

Regulatory

Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical d ...

2020-07-13

Regulatory

Promising safety data for ATOR-1015 "With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinica ...

2020-06-23

Lund, Sweden, June 23, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the United States Patent and Trademark Off ...

2020-06-15

Lund, Sweden, June 15, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the appointment of Marie Svensson as Chief Fina ...

2020-06-10

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High D ...

2020-06-04

Regulatory

Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced ...

2020-06-01

Regulatory

Lund, Sweden, June 1, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 ...